GLP-1 drug and brand comparison: Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda
GLP-1 drug and brand comparison: Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda
A practical comparison of the major GLP-1 and GIP/GLP-1 drugs users ask about most: how the molecules differ, what the branded labels mean, which titration windows are longest, and where GI burden tends to show up.
Users comparing semaglutide, tirzepatide, and liraglutide pathways, and support teams who need one page that separates brand noise from molecule-level reality.
- Which brands map to which molecules and indications
- How semaglutide, tirzepatide, and liraglutide differ in cadence and escalation length
- Which drugs show the heaviest GI burden signals in obesity labeling
- Why users should compare molecule plus support path, not just brand popularity
- Start by identifying the molecule first, then the brand label and indication.
- Look at cadence, titration length, and major GI burden instead of relying on one headline efficacy number.
- Distinguish weekly obesity products from diabetes products that users are often trying to interpret through social media.
- Do not confuse a telehealth platform with the drug itself.
Drug and brand snapshot
| Molecule / brand | Typical cadence | Standard climb | Where users feel the friction |
|---|---|---|---|
| Semaglutide / Wegovy | Weekly | 0.25 → 2.4 mg over about 16 weeks | Start window and every escalation; nausea, diarrhea, constipation remain the main comfort issues |
| Semaglutide / Ozempic | Weekly | Diabetes-labeled path, often socially compared by users anyway | Users often import Ozempic stories into weight-loss expectations even when the label context differs |
| Tirzepatide / Zepbound | Weekly | 2.5 → 15 mg over about 20 weeks | Longer active titration period means more watch windows and more opportunities for avoidable dropout |
| Tirzepatide / Mounjaro | Weekly | Diabetes-labeled path, frequently compared in public discussion | Users often know the brand before they understand the obesity-treatment workflow |
| Liraglutide / Saxenda | Daily | 0.6 → 3.0 mg over about 5 weeks | Daily injection cadence creates its own adherence friction even when the ramp is shorter |
GI burden at a glance
| Symptom | Wegovy 2.4 mg | Zepbound 5 / 10 / 15 mg | Saxenda 3.0 mg |
|---|---|---|---|
| Nausea | 44% | 25% / 29% / 28% | 39.3% |
| Diarrhea | 30% | 19% / 21% / 23% | 20.9% |
| Vomiting | 24% | 8% / 11% / 13% | 15.7% |
| Constipation | 24% | 17% / 14% / 11% | 19.4% |
These are label-level obesity adverse-reaction signals. They are useful for framing journey friction, not for predicting an individual user's exact experience.
Why molecule-level comparison matters more than telehealth branding
Users frequently compare Noom versus Hims or one clinic versus another before they understand the underlying medication path. That is backwards. The molecule, label, dosing cadence, and titration pattern shape the journey much more than the front-end platform.
This is especially important because the same molecule can appear under more than one brand, and the same platform may route users to different therapies depending on supply, coverage, or prescriber judgment.
What separates semaglutide, tirzepatide, and liraglutide in practice
Semaglutide in the obesity context is most visibly associated with Wegovy, while tirzepatide is associated with Zepbound. Ozempic and Mounjaro are diabetes labels that many users know first because of public awareness, but they are not the same thing as the obesity-specific labeled products in user-facing support terms.
Tirzepatide typically carries a longer standard dose climb toward higher maintenance doses. Semaglutide often feels simpler in cadence, but still concentrates tolerability issues around start and escalation windows. Liraglutide carries a daily injection burden and a shorter climb to maintenance, which can still feel demanding because the treatment is encountered every day rather than weekly.
What the GI data says at a high level
Across the obesity labels, semaglutide 2.4 mg shows a higher cumulative GI burden than tirzepatide's labeled obesity doses on many common symptoms, though user experience still varies widely by dose, behavior, and support quality.
The important product insight is not just which number is higher. It is that the timing patterns are predictable enough to build phase-aware support: nausea and diarrhea cluster earlier and around escalations, while constipation and upper-GI friction tend to last longer.
How this should change product design
A knowledge product should not flatten all GLP drugs into one undifferentiated feed. The support windows differ. Tirzepatide's longer climb means longer active management. Semaglutide's GI load means stronger timeline framing. Liraglutide's daily cadence means the treatment is felt differently in routine and adherence behavior.
That is why the library needs both drug-level comparison pages and symptom-level operating pages. One without the other leaves users under-informed.
Is Ozempic the same as Wegovy?
They are both semaglutide brands, but they are different labels with different user contexts. For a weight-management support product, the more relevant comparison is usually molecule plus labeled use, not just whether the brand name is familiar.
Why do so many users compare Zepbound to Wegovy first?
Because those are the most visible obesity-brand labels in the U.S. discussion. But the right comparison still needs dosing path, GI load, coverage reality, and tolerability support, not just headline efficacy.
Does the strongest weight-loss headline automatically mean the best first choice?
No. Tolerability, coverage, prior history, baseline GI risk, and the quality of support often matter just as much as the top-line efficacy signal.